Table 3. Comparison of baseline characteristics of patients with and without postoperative liver failure.
| Baseline characteristics | Liver failure (n=17) | Control (n=37) | P value |
|---|---|---|---|
| Age (years) | 50.53±14.19 | 51.41±9.47 | 0.789 |
| Gender | 0.988 | ||
| Male | 15 (88.23) | 31 (83.78) | |
| Female | 2 (11.76) | 6 (16.22) | |
| RI (%) | 55.67±63.71 | 45.08±38.18 | 0.451 |
| PHRR (%) | 46.04±20.17 | 33.18±17.93 | 0.022* |
| LVpre (cm3) | 704.33±289.01 | 748.97±218.75 | 0.689 |
| LVpost (cm3) | 1,045.43±226.15 | 1,005.61±159.14 | 0.429 |
| BMI (kg/m2) | 23.24±4.11 | 23.27±3.02 | 0.980 |
| Tumor size (cm) | 6.33±3.69 | 5.61±3.66 | 0.507 |
| Multifocality | 7 (41.18) | 10 (27.03) | 0.353 |
| ALT (IU/L) | 42.24±25.93 | 128.68±267.97 | 0.060 |
| AST (IU/L) | 40.82±26.97 | 150.86±363.00 | 0.075 |
| ALP (IU/L) | 94.65±27.23 | 103.27±47.13 | 0.410 |
| GGT (IU/L) | 96.35±49.41 | 105.00±88.50 | 0.648 |
| AST/ALT | 1.03±0.29 | 1.09±0.41 | 0.607 |
| TP (g/L) | 70.09±6.99 | 67.95±9.20 | 0.351 |
| ALB (g/L) | 42.82±4.89 | 40.98±5.73 | 0.232 |
| TBIL (μmol/L) | 15.81±8.57 | 13.68±4.83 | 0.351 |
| DBIL (μmol/l) | 5.85±4.94 | 4.98±2.44 | 0.497 |
| HGB (g/L) | 145.18±22.34 | 139.16±21.23 | 0.358 |
| PLT (109/L) | 150.53±84.28 | 155.49±73.07 | 0.836 |
| PT (s) | 12.92±4.32 | 13.77±4.54 | 0.903 |
| INR | 1.05±0.12 | 1.03±0.15 | 0.710 |
| HBsAg (positive) | 16 (94.12) | 33 (89.19) | 1.000 |
| HBeAg (positive) | 1 (5.88) | 2 (5.41) | 1.000 |
| Anti-HCV (positive) | 1 (5.88) | 0 (0.00) | 0.315 |
| Cirrhosis | 15 (88.24) | 26 (70.27) | 0.152 |
| Ascites | 1 (5.88) | 0 (0.00) | 0.876 |
| High blood pressure | 4 (23.53) | 8 (21.62) | 0.981 |
| Diabetes mellitus | 2 (11.76) | 1 (2.70) | 0.177 |
| BCLC stage | 0.145 | ||
| 0 | 0 (0.00) | 2 (5.41) | |
| A | 8 (4.71) | 22 (59.46) | |
| B | 6 (35.29) | 10 (27.03) | |
| C | 3 (17.65) | 3 (8.11) | |
| ALBI grade | 0.790 | ||
| I | 14 (82.35) | 29 (78.38) | |
| II | 2 (11.76) | 7 (18.92) | |
| III | 1 (5.88) | 1 (2.70) | |
| Type of hepatectomy | 0.149 | ||
| Minor (<3 Couinaud segments) | 7 (41.18) | 23 (62.16) | |
| Major (≥3 Couinaud segments) | 10 (58.82) | 14 (37.84) | |
| Inflammation grade | 0.053 | ||
| G1 | 0 (0.00) | 4 (10.81) | |
| G2 | 5 (29.41) | 19 (51.35) | |
| G3 | 12 (70.59) | 14 (37.84) | |
| Fibrosis stage | 0.004* | ||
| F0–1 | 1 (5.88) | 9 (24.32) | |
| F2–3 | 6 (35.29) | 21 (56.76) | |
| F4 | 10 (58.82) | 7 (18.92) | |
| LS value (kPa) | 4.97±1.28 | 3.94±1.51 | 0.018* |
Data are represented in mean ± SD or n (%). Data were evaluated by independent t-test or Mann-Whitney U test for continuous variables and chi-square test or Fisher’s exact test for categorical variables. *, P<0.05. RI, regeneration index; PHRR, parenchymal hepatic resection rate; LVpre, volume of preoperative future liver remnant; LVpost, volume of postoperative liver remnant; BMI, body mass index; ALT, alanine aminotransferase; AST, aspartate aminotransferase; ALP, alkaline phosphatase; GGT, γ-glutamyl transferase; TP, total protein; ALB, albumin; TBIL, total bilirubin; DBIL, direct bilirubin; HGB, hemoglobin; PLT, platelet count; PT, prothrombin time; INR, international normalized ratio; HBsAg, hepatitis B surface antigen; HBeAg, hepatitis B e antigen; anti-HCV, hepatitis C virus antibody; BCLC, Barcelona Clinic Liver Cancer; ALBI, albumin-bilirubin; LS, liver stiffness.